POINT Biopharma Global Inc. , a company engaged in the discovery, development, and global access to life-changing radiopharmaceuticals, presented a poster on its FAP-Alpha targeted program PNT2004 at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

The poster titled “Pre-clinical characterization of the novel Fibroblast Activation Protein (FAP) targeting ligand PNT6555 for the imaging and therapy of cancer” highlighted the lead candidate of the PNT2004 program, PNT6555, showing that 68Ga-PNT6555 is an effective imaging agent, with strong tumor targeting, low background in normal tissues and rapid clearance via urinary excretion and177Lu-PNT6555 shows prolonged tumor retention out to 168 hours post-injection. It also mentioned that theefficacy studies with 177Lu-PNT6555 or 225Ac-PNT6555 demonstrate compelling and dose-responsive inhibition of HEK-mFAP tumor growth.

To read more please visit:

POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting

Source: POINT